|Bid||1.4200 x 900|
|Ask||1.4300 x 3200|
|Day's range||1.4000 - 1.4600|
|52-week range||1.0900 - 2.9000|
|Beta (5Y monthly)||1.15|
|PE ratio (TTM)||0.65|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Chimerix ( NASDAQ:CMRX ) First Quarter 2023 Results Key Financial Results Revenue: US$283.0k (up by US$268.0k from 1Q...
Chimerix (CMRX) delivered earnings and revenue surprises of 0% and 19.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Every investor in Chimerix, Inc. ( NASDAQ:CMRX ) should be aware of the most powerful shareholder groups. We can see...
Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Chimerix, Vista Oil & Gas and Arcus Biosciences have been highlighted in this Screen of The Week article.
Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.
Chimerix (CMRX) delivered earnings and revenue surprises of 30.95% and 84.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific's (BSX) Q3 revenues reflect double-digit organic revenue growth across the majority of its businesses.
Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.
A look at the shareholders of Chimerix, Inc. ( NASDAQ:CMRX ) can tell us which group is most powerful. We can see that...
Investors need to pay close attention to Chimerix (CMRX) stock based on the movements in the options market lately.
With me on today's call are president and chief executive officer, Mike Sherman; chief medical officer, Allen Melemed; chief financial and business officer, Mike Andriole; chief science officer, Randall Lanier; and our chief technology officer of Imipridones, Josh Allen. Before we begin, I'd like to remind you that the statements made on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors.
Yahoo Finance Live anchors report that WHO has declared Monkeypox a global health emergency.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
The recent price decline of 24% in Chimerix, Inc.'s ( NASDAQ:CMRX ) stock may have disappointed insiders who bought...